Skip to content
ESPT
MARKETS / NASDAQ / Health care / Medical devices and instruments / OSUR
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

Orasure Technologies Inc. OSUR

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$115.0M
▼ 38.1% YoY
$-68.7M
$-53.2M
▼ 325.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The company's business is principally comprised of the development, manufacture, marketing, sale and distribution of diagnostics products and sample management solutions. Its diagnostic products include tests for diseases including HIV, Hepatitis C virus, Syphilis, Sickle Cell and COVID-19 that are performed on a rapid basis at the point of care. The company's business also includes sample management solutions and services used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers. It manufactures all of the proprietary chemistry and assay cards for its InteliSwab COVID-19 Rapid Tests in its Bethlehem, Pennsylvania facilities. One non-commercial customer accounted for approximately 3% of its consolidated net revenues for the year ended December 31, 2025. As of December 31, 2025, the company had 500 full-time employees.

Written from the business description in ORASURE TECHNOLOGIES INC's annual report to the U.S. Securities and Exchange Commission, filed 9 March 2026. Every sentence was checked against that document before publication.

Growth

USD 115.0M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 115.0 · Net income -68.7
150.0M300.0M-25.0M-50.0M
2009201220152018202120242025
Compound annual growth
−33.3%
−7.7%
−0.4%
+2.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −7.7% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−60 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -62.6% · Net -59.8%
10%20%-20%-40%-60%
200920172025
ROE
FY2025 · ROE -18.3%
5%10%-5%-10%-15%
200920172025
Three returns, three denominators.
Gross margin41.9%
Operating margin-62.6%
Net margin-59.8%
EBITDAUSD -61.8M

Each USD of equity lost 18 cents this year.

Cash & shareholders

USD 15.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -53.2
50.0M100.0M-25.0M-50.0M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 15.0
10.0M20.0M-25.0M-50.0M
200920112013201520172019202120232025
Dividends paid·
Net buybacksUSD 15.0M
Share of profit-21.9%
Consecutive raises·

USD 15.0M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 403.2M
EquityUSD 340.8M
CashUSD 199.3M
Current ratio6.58×

Equity funds 85% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
OSUR, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.10.20.40.40.20.20.20.20.20.10.10.10.10.10.10.10.1
Operating income $B−0.1−0.00.0−0.0−0.0−0.00.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.00.1−0.00.00.00.00.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.0−0.0−0.0−0.0◌−0.0
Net income $B−0.1−0.00.1−0.0−0.0−0.00.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.10.00.1−0.1−0.1−0.00.00.00.00.00.00.00.0−0.0−0.00.0−0.0
EPS, diluted $−0.94−0.260.72−0.24−0.32−0.220.270.330.510.350.14−0.08−0.20−0.29−0.19−0.08−0.17
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %−18.3−4.613.5−4.6−5.9−4.25.67.513.911.45.1−2.9−6.8−11.2−8.7−3.4−7.5
Shares out B0.070.070.070.070.070.070.060.060.060.060.060.060.060.060.050.05◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 82 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: the share count is not tagged before 2010. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image